Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of rosacea
3.2.1.2 Advancements in combination therapies and drugs
3.2.1.3 Rising awareness and diagnosis
3.2.1.4 Improving access to diagnosis and treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs and availability of alternative treatment options
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Erythematotelangiectatic rosacea
5.3 Papulopustular rosacea
5.4 Ocular rosacea
5.5 Phymatous rosacea
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Topical
6.4 Other treatment types
Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Antibiotic
7.3 Alpha agonist
7.4 Retinoid
7.5 Corticosteroid
7.6 Immunosuppressant
7.7 Other drug classes
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Aclaris Therapeutics
10.2 Colorescience, Inc.
10.3 Croda International Plc
10.4 Dr. Reddy’s Laboratories Ltd
10.5 Galderma
10.6 Journey Medical Corporation
10.7 Leopharma
10.8 Lupin
10.9 Maruho Co.,Ltd.
10.10 Merck & Co., Inc
10.11 Mylan N.V.
10.12 Perrigo Company plc
10.13 PRUGEN
10.14 Sol-Gel Technologies Ltd
